Sveits - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - epoetinum alfa - soluzione iniettabile in siringhe preriempite - epoetinum alfa 9000 u.i., polysorbatum 80, natrii chloridum, natrii dihydrogenophosphas dihydricus, dinatrii phosphas dihydricus, glycinum, aqua ad iniectabile q.s. ad solutionem pro 0.9 ml. - stimolazione dell'eritropoiesi - biotechnologika

Sveits - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - epoetinum alfa - soluzione iniettabile in siringhe preriempite - epoetinum alfa 10000 u.i., polysorbatum 80, natrii chloridum, natrii dihydrogenophosphas dihydricus, dinatrii phosphas dihydricus, glycinum, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - stimolazione dell'eritropoiesi - biotechnologika

Den europeiske union - italiensk - EMA (European Medicines Agency)

bayer ag - riociguat - ipertensione, polmonare - antipertensivi per l'ipertensione arteriosa polmonare - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. l'efficacia è stata dimostrata in un pah della popolazione eziologie di idiopatica o ereditaria ipa o pah associata a malattia del tessuto connettivo. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.

Italia - italiensk - Ministero della Salute

dechra regulatory b.v. - ialuronato sodico - ialuronato sodico - 17 mg - hyaluronic acid

Sveits - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - fingolimodum - capsule - fingolimodum 0.5 mg ut fingolimodi hydrochloridum, amylum pregelificatum, natrii laurilsulfas corresp. natrium 0.045 mg, kapselhülle: e 171, e 172 (flavum), gelatina, drucktinte: lacca, propylenglycolum, ammoniae solutio concentrata, e 172 (nigrum), kalii hydroxidum, pro capsula. - multiple sklerose - synthetika

Sveits - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - fingolimodum - capsule - fingolimodum 0.25 mg ut fingolimodi hydrochloridum, amylum pregelificatum, natrii laurilsulfas corresp. natrium < 23 mg, kapselhülle: gelatina, e 171, drucktinte: lacca, propylenglycolum, ammoniae solutio concentrata, e 172 (nigrum), kalii hydroxidum pro capsula. - multiple sklerose - synthetika

Sveits - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - fingolimodum - capsule - fingolimodum 0.5 mg ut fingolimodi hydrochloridum, amylum pregelificatum, natrii laurilsulfas corresp. natrium < 23 mg, kapselhülle: gelatina, e 171, e 172 (flavum), drucktinte: lacca, propylenglycolum, ammoniae solutio concentrata, e 172 (nigrum), kalii hydroxidum pro capsula. - multiple sklerose - synthetika

Italia - italiensk - AIFA (Agenzia Italiana del Farmaco)

monico s.p.a. - elettroliti - elettroliti

Italia - italiensk - AIFA (Agenzia Italiana del Farmaco)

monico s.p.a. - elettroliti - elettroliti

Italia - italiensk - AIFA (Agenzia Italiana del Farmaco)

eurospital s.p.a. - elettroliti - elettroliti